Valence-Logo
Beliebt
Anmelden
Loading data for ADPT — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Adaptive Biotechnologies ...

NasdaqGS: ADPT · Echtzeitkurs · USD
25.49
+0.93 (3.79%)
Zum Schluss: Aug 18, 2026, 8:00 PM
24.56
+0.00%
Vorbörslich: 4:00 AM

Adaptive Biotechnologies Corporation (ADPT) Stock Price, Analysis & Data

3.79%

Keine Daten verfügbar

Geld18.68
Marktkapitalisierung3.92 Mrd
Umsatz (TTM)308.08 Mio
Nettogewinn (TTM)-63.85 Mio
Beta2.09
EPS (ttm)-0.4
KGV (TTM)n/a
Forward-KGV-132.95
KBV (TTM)27.35
KUV (TTM)12.72
Earnings DateNov 4, 2026
Brief32.57
Volumen2,088,644
Ø Vol. (20D)2,958,925
Eröffnung25.38
Vortagesschluss24.56
Tagesspanne25.16 - 26.16
52-Wk Range12.00 - 26.16
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datumn/a

Über ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining num...

[Mehr lesen]
Branche Diagnostics & Research
Sektor Healthcare
IPO Datum Jun 27, 2019
Mitarbeiter 624
Börse NasdaqGS
Tickersymbol ADPT
Website https://www.adaptivebiotech.com
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Adaptive Biotechnologies 276.98 Mio, ein Anstieg von 54.77% im Vergleich zum Vorjahr (178.96 Mio). Der Gewinn lag bei -59.5 Mio, ein Rückgang von -62.69 %.

Finanzberichte

Gewinnüberraschung

Adaptive Biotechnologies hat die Quartalszahlen am Jul 29, 2026 veröffentlicht:
  • Umsatz von n/a verfehlt die Erwartungen um $0, mit -100.00% Rückgang im Jahresvergleich.
  • EPS von -0.25 verfehlt die Erwartungen um -0.12, mit -47.06% Rückgang im Jahresvergleich.

    • Nächste Ergebnisveröffentlichung

    Adaptive Biotechnologies Corporation wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 4, 2026, während der Handelszeiten.
    Analysten erwarten einen Umsatz von ... Upgrade
    news image

    vor 2 Wochen · GuruFocus.com

    Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

    Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

    news image

    vor 2 Wochen · Zacks

    Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

    While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key m...

    news image

    vor 2 Wochen · Zacks

    Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

    Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

    news image

    vor 2 Wochen · MarketBeat

    Adaptive Biotechnologies Q2 Earnings Call Highlights

    Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year reve...

    news image

    vor 3 Wochen · Simply Wall St.

    Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In

    Investors are watching Adaptive Biotechnologies (ADPT) after forecasts pointed to a reduced quarterly loss of $0.13 per share and 12.6% revenue growth for the June 2026 quarter, alongside its track re...

    Seite 1 von 2